BAM
DNLI icon

Baldrige Asset Management’s Denali Therapeutics DNLI Stock Holding History

Baldrige Asset Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		$0 Buy
+11
New +$303 ﹤0.01% 415

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

Baldrige Asset Management's DNLI Position: Q1 2023 in Review

Baldrige Asset Management opened a new position in Denali Therapeutics (DNLI) in Q1 2023: 11 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #415 among its holdings.

202 funds tracked by Wall St. Rank hold DNLI as of Q1 2023.

  • Baldrige Asset Management held 11 shares of Denali Therapeutics worth $0 as of Q1 2023.
  • Denali Therapeutics was a new Baldrige Asset Management position in Q1 2023.
  • Denali Therapeutics made up ﹤0.01% of Baldrige Asset Management's portfolio in Q1 2023, its #415 holding.
  • 202 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2023.

Based on Baldrige Asset Management's 13F filing for Q1 2023, filed 17 Apr 2023.